These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36897009)

  • 1. Identifying the patient with heart failure to be treated with vericiguat.
    Escobar Cervantes C; Esteban Fernández A; Recio Mayoral A; Mirabet S; González Costello J; Rubio Gracia J; Núñez Villota J; González Franco Á; Bonilla Palomas JL
    Curr Med Res Opin; 2023 May; 39(5):661-669. PubMed ID: 36897009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
    Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
    JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat.
    Coats AJS; Tolppanen H
    Drugs; 2021 Sep; 81(14):1599-1604. PubMed ID: 34478114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care.
    Escobar C; Luis-Bonilla J; Crespo-Leiro MG; Esteban-Fernández A; Farré N; Garcia A; Nuñez J
    Expert Opin Pharmacother; 2022 Oct; 23(14):1589-1599. PubMed ID: 35995759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
    Kang C; Lamb YN
    Am J Cardiovasc Drugs; 2022 Jul; 22(4):451-459. PubMed ID: 35624347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vericiguat for the treatment of heart failure with reduced ejection fraction.
    Siddiqi AK; Greene SJ; Fudim M; Mentz RJ; Butler J; Khan MS
    Expert Rev Cardiovasc Ther; 2023 Apr; 21(4):245-257. PubMed ID: 36881733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vericiguat for Heart Failure with Reduced Ejection Fraction.
    Lombardi CM; Cimino G; Pagnesi M; Dell'Aquila A; Tomasoni D; Ravera A; Inciardi R; Carubelli V; Vizzardi E; Nodari S; Emdin M; Aimo A
    Curr Cardiol Rep; 2021 Aug; 23(10):144. PubMed ID: 34410527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging concepts in heart failure management and treatment: focus on vericiguat.
    Kaplinsky E; Perrone S; Barbagelata A
    Drugs Context; 2023; 12():. PubMed ID: 36660012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options.
    Hulot JS; Trochu JN; Donal E; Galinier M; Logeart D; De Groote P; Juillière Y
    Expert Opin Pharmacother; 2021 Oct; 22(14):1847-1855. PubMed ID: 34074190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vericiguat in heart failure: From scientific evidence to clinical practice.
    González-Juanatey JR; Anguita-Sánchez M; Bayes-Genís A; Comín-Colet J; García-Quintana A; Recio-Mayoral A; Zamorano-Gómez JL; Cepeda-Rodrigo JM; Manzano L
    Rev Clin Esp (Barc); 2022; 222(6):359-369. PubMed ID: 35473692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart Failure With Reduced Ejection Fraction: A Review.
    Murphy SP; Ibrahim NE; Januzzi JL
    JAMA; 2020 Aug; 324(5):488-504. PubMed ID: 32749493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction.
    Aimo A; Castiglione V; Vergaro G; Panichella G; Senni M; Lombardi CM; Emdin M
    Heart Fail Rev; 2022 Jul; 27(4):1165-1171. PubMed ID: 34291399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations.
    Kassis-George H; Verlinden NJ; Fu S; Kanwar M
    Ther Clin Risk Manag; 2022; 18():315-322. PubMed ID: 35386181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vericiguat in Heart Failure: Characteristics, Scientific Evidence and Potential Clinical Applications.
    Vannuccini F; Campora A; Barilli M; Palazzuoli A
    Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum.
    Butler J; Usman MS; Anstrom KJ; Blaustein RO; Bonaca MP; Ezekowitz JA; Freitas C; Lam CSP; Lewis EF; Lindenfeld J; McMullan CJ; Mentz RJ; O'Connor C; Rosano GMC; Saldarriaga CI; Senni M; Udelson J; Voors AA; Zannad F
    Eur J Heart Fail; 2022 Nov; 24(11):2029-2036. PubMed ID: 36250238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vericiguat: A Novel Oral Soluble Guanylate Cyclase Stimulator for the Treatment of Heart Failure.
    Campbell N; Kalabalik-Hoganson J; Frey K
    Ann Pharmacother; 2022 May; 56(5):600-608. PubMed ID: 34431706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vericiguat-new treatment option for patients with heart failure : Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA)].
    Bauersachs J; Nitschmann S
    Internist (Berl); 2020 Sep; 61(9):989-991. PubMed ID: 32591849
    [No Abstract]   [Full Text] [Related]  

  • 19. Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat.
    Sepehrvand N; Islam S; Dover DC; Kaul P; McAlister FA; Armstrong PW; Ezekowitz JA
    J Card Fail; 2022 Aug; 28(8):1298-1308. PubMed ID: 35589087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week.
    Emdin M; Aimo A; Castiglione V; Vergaro G; Georgiopoulos G; Saccaro LF; Lombardi CM; Passino C; Cerbai E; Metra M; Senni M
    J Am Coll Cardiol; 2020 Oct; 76(15):1795-1807. PubMed ID: 33032741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.